木瓦
医学
水痘
皮疹
接种疫苗
水痘带状疱疹病毒
神经痛
皮肤病科
病毒
背
病毒学
儿科
免疫学
神经病理性疼痛
麻醉
解剖
作者
Radhika A. Shah,Allison L Limmer,Crystal E Nwannunu,Ravi R Patel,Uyen Ngoc Mui,Stephen K. Tyring
出处
期刊:PubMed
日期:2019-07-01
卷期号:24 (4): 5-7
被引量:10
摘要
Herpes zoster (HZ), also known as shingles, results from reactivation of the latent varicella-zoster virus (VZV), which commonly causes chickenpox in childhood. Greater than 90% of adults are infected with this virus, putting them at risk for reactivation. HZ presents as a painful, vesicular rash distributed in a unilateral and dermatomal pattern along dorsal root or cranial nerve ganglia. The rash often presents with prodromal symptoms and progresses to include clear vesicular clusters, evolving through stages of pustulation, ulceration, and crusting. HZ therapy currently involves the use of antiviral agents and pain management; however, HZ prophylaxis has been strongly recommended in older adults through vaccination with a live attenuated vaccine, Zostavax®. A new recombinant subunit vaccine, HZ/su (Shingrix®), is the subject of this review. In clinical trials, HZ/su demonstrated an overall vaccine efficacy of 97.2% among participants 50 years of age or older, indicating a significantly reduced risk of HZ in these individuals. Shingrix® was approved by the US FDA in October 2017 as HZ prophylaxis.
科研通智能强力驱动
Strongly Powered by AbleSci AI